Isabl Inc. is a biotechnology startup that focuses on developing whole-genome and RNA sequencing diagnostic assays for cancer. The company was founded in 2020, following a period of technology incubation at MSKCC from 2015 to 2019. Isabl also participated in Y Combinator's Winter 2020 batch. Notably, the company secured $3M in seed funding from Two Sigma Ventures, Y Combinator, and BoxOne Ventures, showcasing confidence from prominent investors. In 2021, Isabl received FDA Breakthrough Device designation, recognizing the potential impact of its cancer diagnostic tests. Additionally, the company was awarded a $2M direct-to-phase-2 SBIR grant from the National Cancer Institute to advance its specialized test targeting pediatric and rare solid cancers, further cementing its position in the industry. With founders Dr. Elli Papaemmanuil, Dr. Andrew Kung, and Juan Medina at the helm, Isabl amalgamates deep expertise in precision medicine, computational biology, and software engineering, supported by a strong track record in biomarker discovery and clinical decision support.
Isabl Inc.
Pioneering precise cancer diagnostics through advanced sequencing technology and expert-driven research.
General Information
BounceWatch is an independent company data service, not affiliated with Isabl Inc.. To contact Isabl Inc., visit isabl.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Isabl Inc. compare?
A PDF of Isabl Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Isabl Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Isabl Inc.
Business keywords: precision medicine, cancer diagnostics, whole-genome sequencing, RNA sequencing, biomarker discovery, clinical decision support, startups, investments, Y Combinator, FDA Breakthrough Device, NCI grant, oncology research, startup funding
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | $2.00M | 1 |
National Cancer Institute
|
01 Apr 2023 |
| Seed Round | $2.85M | 4 |
|
18 May 2022 |
| Pre Seed Round | $150.00K | 1 |
|
01 Jun 2020 |
Isabl Inc. Alternatives & Competitors
View All Alternatives
Genomic and theranostic company specializing in precision medicine for the treatment of cancer and g...
Our Vision: To be the world’s leading liquid biopsy company providing valuable clinical information...
Precision genome analytics and novel patient data collections for improving cancer treatment outcome...
FAQ About Isabl Inc.
Source: BounceWatch company record for Isabl Inc., https://bouncewatch.com/company/isabl-inc, updated 24 December 2024. When citing, please name BounceWatch and link this page.
